ClinicalTrials.gg
CompletedNCT06408857Updated Jun 3, 2026

Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

A Phase 1 interventional study of MAM01 300 mg SC and MAM01 300 mg IM in Healthy Volunteers, sponsored by Gates Medical Research Institute. Completed at 2 sites in Uganda. Open to participants aged 3 Months to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Gates Medical Research Institute · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
3 Months to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies in Malaria with a site in Uganda — 10 open to participants now, 14 under way, 1 of them phase 3. Malaria · Uganda.

Enrollment
66th of 80
125 · median 458
Started
2025
with 3 others
Phase 1
5 of 98
1 open now
Registered
87th of 98
by date

Among the 98 studies in Malaria with a site in Uganda, this one is the 66th largest by enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2025, is one of 5 in phase 1, and was the 87th registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

10 of the 98 studies in Malaria with a site in Uganda are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Uganda have not opened yet or have stopped. Only those recruiting at a site in Uganda →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 3 Months to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Malaria with a site in Uganda, or all of them as a file.
02

Study summary

This study will test a new drug (MAM01) to find which doses are safe and could help prevent people from getting malaria for at least 4 months. The study will take place in parts of Africa where malaria is common. Part A is an open-label study conducted in healthy adults whereas Part B is double-blind study conducted in young children and infants. Both the parts will evaluate the safety, tolerability and pharmacokinetics of MAM01.

Read the detailed description

This is a Phase 1b, age de-escalation/dose escalation trial that will be conducted in a setting of perennial Plasmodium falciparum (malaria parasite) transmission in Africa. The study will be conducted in 2 parts: Part A (Dose Escalation in Adults); Part B (Age De-escalation/Dose Escalation in Younger Children and infants).

03

Conditions studied

  • Healthy Volunteers

Keywords

  • Malaria
  • Plasmodium falciparum
  • MAM01
  • De-Escalation
  • Dose Escalation
  • Perennial Malaria Transmission
  • Antibody
  • Monoclonal
  • Prevention
  • Pediatric
  • mAb-1797
04

Who can participate

Ages eligible
3 Months to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PART A

  • Male or female adults aged 18 to 55 years inclusive at the time of signing the form (ICF), who are capable of, and willing to provide, informed consent
  • Healthy, as determined by Investigator assessment, including medical history, physical examination, and screening laboratory results
  • All dosing groups: level ≥ 8 grams per deciliter (g/dL)
  • All dosing groups: living within local jurisdiction of trial site(s) and available for the duration of the trial for all cohorts
  • Female participants of must be nonpregnant and agree to avoid becoming pregnant by using an acceptable method

PART B

  • Age Cohort 2: male or female children aged 2 years to \<5 years at the time their parent or Legally Authorized Representative (LAR) signs the ICF
  • Age Cohort 3: male or female children aged 12 months to \<24 months at the time their parent or LAR signs the ICF
  • Age Cohort 4: male or female infant children aged 3 months to \<12 months and weighing at least 5 kilograms (kg) at the time their parent or LAR signs the ICF
  • Healthy, as determined by Investigator assessment, including medical history, physical examination, and screening laboratory results
  • Hemoglobin level ≥ 8g/dL
  • Height and weight Z-scores ≥-2
  • Living within local jurisdiction of trial site(s) and available for the duration of the trial

Exclusion criteria

Exclusion Criteria:

PART A \& PART B

  • Within 48 hours prior to randomization, acute febrile illness

    • Sickle cell disease or history of splenectomy
    • Use of antimalarial chemoprevention or treatment, and/or antibiotics with known antimalarial effects (eg, clotrimoxazole, azithromycin, tetracyclines) within 30 days prior to dosing
    • Enrolled in another clinical trial within 90 days prior to Screening or planning to participate in another trial during, or within 1 year following, their participation in this trial
    • Received any doses of a malaria vaccine or other monoclonal antibodies (mAb) to Pf
    • Eligible to receive a malaria vaccine (RTS, S/AS01 or R21/Matrix-M) at screening or if it is expected to become available during the period of the trial.
    • History of allergy or or to trial drugs (including those used as empirically treatment for Pf to clear any existing parasitemia), or related substances
    • Any history of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the trial
    • History of any disease or immunodeficiency or other impairment to the immune system, including infection
    • Use of chronic (≥ 14 days) agents including systemic (eg, prednisone >10 milligrams per day [mg/day]) within 30 days prior to dosing. Use of inhaled or topical corticosteroids is permitted
    • Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or disorder requiring special precautions) or significant bruising with blood draws
    • Receipt of immunoglobulins and/or blood products within the past 6 months
    • Any current uncontrolled medical or psychiatric condition, or substance abuse problems that in the opinion of the Investigator, will make it unlikely for participant to comply with the protocol, may interfere with study assessments, or could jeopardize the safety of the participant
    • Any contraindication for a subcutaneous injection, intravenous injection, or intramuscular injection, as applicable
    • For Part A, female participants who are breastfeeding, pregnant, or unable or unwilling to adhere to required
    • For Part B, in the opinion of the Investigator, the parent or LAR may not be able to ensure participant compliance with the requirements of the trial
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Part A: Cohort 1a (Healthy Adults): 300 milligrams (mg) MAM01 subcutaneously (SC)

    Participants will receive MAM01.

    Drug: MAM01 300 mg SC

  • Experimental
    Part A: Cohort 1b (Healthy Adults): 300 mg MAM01 intramuscularly (IM)

    Participants will receive MAM01.

    Drug: MAM01 300 mg IM

  • Experimental
    Part A: Cohort 1c (Healthy Adults): 2000 mg MAM01 intravenously (IV)

    Participants will receive MAM01.

    Drug: MAM01 2000 mg IV

  • Experimental
    Part B: Cohort 2a (Healthy Younger Children): 190 mg MAM01 or placebo SC

    Participants will be randomized in 3:1 ratio (MAM01 : PBO)

    Drug: MAM01 190 mg SC · Drug: Placebo SC

  • Experimental
    Part B: Cohort 2b (Healthy Younger Children): 225 mg MAM01 or placebo SC

    Participants will be randomized in 3:1 ratio (MAM01 : PBO)

    Drug: MAM01 225 mg SC · Drug: Placebo SC

  • Experimental
    Part B: Cohort 3a (Healthy Infants): 150 mg MAM01 or placebo SC

    Participants will be randomized in 3:1 ratio (MAM01 : PBO)

    Drug: MAM01 150 mg SC · Drug: Placebo SC

  • Experimental
    Part B: Cohort 3b (Healthy Infants): 150 mg MAM01 or placebo IM

    Participants will be randomized in 3:1 ratio (MAM01 : PBO)

    Drug: MAM01 150 mg IM · Drug: Placebo IM

  • Experimental
    Part B: Cohort 3c (Healthy Infants): 150 mg MAM01 or placebo IV

    Participants will be randomized in 3:1 ratio (MAM01 : PBO)

    Drug: MAM01 150 mg IV · Drug: Placebo IV

  • Experimental
    Part B: Cohort 4a (Healthy Infants): 150 mg MAM01 or placebo SC

    Participants will be randomized in 3:1 ratio (MAM01 : PBO)

    Drug: MAM01 150 mg SC · Drug: Placebo SC

  • Experimental
    Part B: Cohort 4b (Healthy Infants): 150 mg MAM01 or placebo IM

    Participants will be randomized in 3:1 ratio (MAM01 : PBO)

    Drug: MAM01 150 mg IM · Drug: Placebo IM

  • Experimental
    Part B: Cohort 4c (Healthy Infants): 150 mg MAM01 or placebo IV

    Participants will be randomized in 3:1 ratio (MAM01: PBO)

    Drug: MAM01 150 mg IV · Drug: Placebo IV

Interventions

  • DrugMAM01 300 mg SC

    MAM01 300 mg will be administered SC

  • DrugMAM01 300 mg IM

    MAM01 300 mg will be administered IM route

  • DrugMAM01 2000 mg IV

    MAM01 2000 mg will be administered IV

  • DrugMAM01 190 mg SC

    MAM01 190 mg will be administered SC

  • DrugMAM01 225 mg SC

    MAM01 225 mg will be administered SC

  • DrugMAM01 150 mg SC

    MAM01 150 mg will be administered SC

  • DrugMAM01 150 mg IM

    MAM01 150 mg will be administered IM

  • DrugMAM01 150 mg IV

    MAM01 150 mg will be administered IV

  • DrugPlacebo SC

    Placebo will be administered SC

  • DrugPlacebo IV

    Placebo will be administered IV.

  • DrugPlacebo IM

    Placebo will be administered IM

06

What researchers measure

Primary outcomes

  1. Number of participants reporting Treatment-emergent adverse events (TEAEs)

    Time frame: Up to 28 days post dose (Part A and B)

  2. Number of participants reporting serious adverse events (SAEs), adverse events of special interest (AESI), and AEs leading to discontinuation

    Time frame: Up to 182 days post dose

  3. Number of participants reporting solicited systemic AEs and solicited injection site AEs (applicable to IM dosing)

    Time frame: Up to 7 days post dose

  4. Number of participants reporting solicited systemic AEs and solicited injection site AEs (applicable to SC dosing)

    Time frame: Up to 7 days post dose

Secondary outcomes

  1. Percentage of participants with graded abnormal clinical hematology and chemistry laboratory results

    Time frame: Up to 28 days post dose

  2. Maximal observed blood concentration of MAM01 following the first dose (Cmax1)

    Capillary blood samples will be collected for the analysis pharmacokinetic parameters. Blood concentrations of MAM01 will be measured using a validated immunoassay.

    Time frame: Pre- and post-dose (IV dosing groups only) at Day 1, 4, 7, 14, 28, 56, 84, 112, 140, and 182

  3. Concentration at Day 182 (C182)

    Time frame: At Day 182 post first dose

  4. Total Area Under the Concentration Curve (AUC) Day 0 - Day 182

    Time frame: From 0 to 182 days post dose

  5. Percentage of participants with antidrug antibodies (ADAs) to MAM01

    Time frame: At Days 1, 28, 84, and 182

07

Study locations

2 sites
  • JCRC-Joint Clinical Research Centre
    Kampala, 10005, Uganda
  • IDRC-Infectious Disease Research Collaboration, IDRC Tororo Hospital Station Road
    Tororo, 749, Uganda
08

References and documents

Individual participant data

Plan to share: Yes — All IPD data that underlie the results presented herein

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Within 12 months of the study completion date

Access criteria: Anonymized participant-level data may be shared with external researchers in accordance with trial participants' written and executed informed consent and applicable local regulations. Qualified researchers may submit a request along with a research proposal to Gates MRI for review. A data sharing agreement must be in place before any clinical trial data are shared. Additional restrictions may apply due to contractual obligations or regulatory constraints.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in May 2026, 14 months.

Of 64 non-industry phase 1 interventional studies under Malaria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 14 months is close to that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
May 10, 2024
StartActual
Mar 28, 2025
Primary completionActual
May 28, 2026
CompletionActual
May 28, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06408857
Lead sponsor
Gates Medical Research Institute
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Mar 28, 2025
Primary completion
May 28, 2026
Completion
May 28, 2026
Last update
Jun 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion